1,137 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB purchased a new stake in Hologic, Inc. (NASDAQ:HOLX) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 1,137 shares of the medical equipment provider’s stock, valued at approximately $93,000.

Other institutional investors also recently made changes to their positions in the company. Prentiss Smith & Co. Inc. raised its position in shares of Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after buying an additional 130 shares during the period. Covestor Ltd grew its position in Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares during the period. First Horizon Advisors Inc. increased its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Empirical Finance LLC raised its holdings in shares of Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock worth $690,000 after purchasing an additional 147 shares during the period. Finally, Wedmont Private Capital lifted its stake in shares of Hologic by 3.7% in the 3rd quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock valued at $361,000 after purchasing an additional 162 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on HOLX shares. Leerink Partners dropped their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Jefferies Financial Group initiated coverage on shares of Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. Royal Bank of Canada upped their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Mizuho decreased their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $89.50.

Insider Activity

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.75% of the company’s stock.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $71.65 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The firm has a market capitalization of $16.26 billion, a PE ratio of 21.52, a P/E/G ratio of 2.38 and a beta of 0.96. Hologic, Inc. has a 1-year low of $70.36 and a 1-year high of $84.67. The business’s fifty day moving average price is $78.65 and its two-hundred day moving average price is $78.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.89 EPS. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.